微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease

内分泌

关键词内分泌 疾病 肝病

词汇介绍

拓展阅读

解析

alcoholic   英/ælkə'hɒlɪk/   美/,ælkə'hɔlɪk/

释    义   adj. 酒精的,含酒精的

               n. 酒鬼,酗酒者

同根词   alcohol n. 酒精,乙醇

               alcoholize vt. 醇化;变成酒精;浸渍酒精中

例    句   This restaurant does not serve alcoholic beverages. 这家餐厅不卖含酒精的饮料。

 

fatty   英 /'fætɪ/   美 /'fæti/

释    义   adj. 脂肪的;肥胖的;多脂肪的;脂肪过多的

n. 胖子

同根词   fat adj. 肥的,胖的;油腻的;丰满的

               fatly adv. 像胖子般地;丰富地

               fat n. 脂肪,肥肉

               fattening v. 养肥(fatten的ing形式)

               fat vi. 长肥

               fat vt. 养肥;在…中加入脂肪

例    句   Moreover, brain tissue contains a great deal of oxidisable material, particularly in the fatty membranes surrounding nerve cells. 此外,脑组织内含有许多可氧化的物质,特别是绕在神经细胞周围的脂肪膜。

概述

非酒精性脂肪性肝病(NAFLD)是一种常见疾病,是指饮酒很少或不饮酒的人肝脏中多余脂肪堆积的一组疾病。最常见的NAFLD形式是称为脂肪肝的非严重疾病。在脂肪肝中,脂肪在肝细胞中积聚。虽然肝脏中的脂肪不正常,但它本身可能不会损害肝脏。一小部分患有NAFLD的人可能患有更严重的疾病,称为非酒精性脂肪性肝炎(NASH)。在NASH中,脂肪堆积与肝细胞炎症和不同程度的瘢痕形成有关。NASH是一种潜在的严重疾病,可能导致严重的肝脏瘢痕和肝硬化。当肝脏受到严重损害时会发生肝硬化,并且肝细胞逐渐被瘢痕组织

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 nalogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind,placebo-controlled, phase 2a trial复制标题

Pegbelfermin (BMS-986036),一种聚乙二醇化成纤维细胞生长因子21纳乐,用于非酒精性脂肪性肝炎患者: 一项随机、双盲、安慰剂对照的2a期试验

发表时间:2018-12-13

影响因子:59.1

作者: Arun Sanyal

期刊:Lancet

In this multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2a study, we enrolled participants at 17 medical centres throughout the USA. Patients who were eligible for inclusion were aged 21–75 years, were not pregnant and agreed to follow instructions on methods of contraception, had a diagnosis of non-alcoholic steatohepatitis (stage 1–3 with Non-Alcoholic Steatohepatitis Clinical Research Network fibrosis staging)17 based on a liver biopsy that had been assessed at local laboratories 1 year or less before lead-in, a BMI of at least 25 kg/m², and hepatic fat fraction of at least 10%, as assessed by magnetic resonance imaging-proton density fat fraction (MRIPDFF) during screening. Patients were excluded if they had evidence of a medical condition that contributed to chronic liver disease other than non-alcoholic steatohepatitis, evidence of cirrhosis, decompensated liver disease, uncontrolled or poorly controlled diabetes (indicated by, for example, a glycated haemoglobin measurement of at least 9∙5%), drug or alcohol abuse within the previous year or excessive alcohol consumption, bone trauma, fracture, or bone surgery within 8 weeks of screening, blood transfusion or major surgery within 6 weeks of screening, or any clinically significant deviation from normal values in physical examination or clinical laboratory determinations beyond reference values for the target patient population. The study protocol (Bristol-Myers Squibb reference no. MB130–045) was approved by the institutional review board or independent ethics committee at each participating institution before study initiation and all patients provided written informed consent before participating in the study.

译文

在这项多中心,随机,双盲,安慰剂对照,平行组,2a期研究中,我们在全美17个医疗中心招募了参与者。符合纳入条件的患者年龄为21-75岁,未怀孕并同意遵守避孕方法的指示,诊断为非酒精性脂肪性肝炎(1-3期非酒精性脂肪性肝炎临床研究网络纤维化分期) 17基于肝脏活组织检查,通过磁共振成像 - 质子评估,在导入前1年或更短时间内在当地实验室进行评估,BMI至少为25 kg /m²,肝脂肪分数至少为10%筛选期间的密度脂肪分数(MRIPDFF)。如果他们有证据证明除了非酒精性脂肪性肝炎之外的慢性肝病的病情,肝硬化证据,肝功能失代偿,糖尿病无法控制或控制不佳(例如,糖尿病血红蛋白测量值为至少9∙5%),上一年内吸毒或酗酒或过度饮酒,骨质创伤,骨折或骨手术8周内筛查,输血或大手术后6周,或任何临床显着偏差从物理检查或临床实验室测定中的正常值超过目标患者群体的参考值。研究方案(Bristol-Myers Squibb参考编号MB130-045)在研究开始前由每个参与机构的机构审查委员会或独立伦理委员会批准,并且所有患者在参与研究之前提供了书面知情同意书。